Table 3.

Ongoing clinical trials evaluating adoptive cell therapy and vaccine therapy for KRAS-mutant malignancy

Agents	Other Agents	Phase	Cancer Type	Study Description	ClinicalTrials.gov Identifier
G12V-specific TCR transduced T-cell therapy	• Cyclophosphamide and fludarabine before infusion • Anti-PD-1 inhibitor if needed	I/II	Advanced pancreatic cancer with KRAS G12V mutation and HLA-A*11:01 allele	Mutant KRAS G12V-specific TCR transduced T Cell therapy for advanced pancreatic cancer	NCT04146298
Anti-KRAS G12V murine TCR	• Cyclophosphamide and fludarabine before infusion • Aldesleukin (high-dose interleukin-2)	I/II	Advanced cancer harboring KRAS G12V mutation	Administering peripheral blood lymphocytes transduced with a murine t-cell receptor recognizing the G12V variant of mutated RAS in HLA-A*11:01 patients	NCT03190941
Anti-KRAS G12D murine TCR	• Cyclophosphamide and fludarabine before infusion • Aldesleukin (high-dose interleukin-2)	I/II	Advanced cancer harboring KRAS G12D mutation	Administering peripheral blood lymphocytes transduced with a murine t-cell receptor recognizing the G12D variant of mutated RAS in HLA-A*11:01 patients	NCT03745326
mRNA-5671 vaccine (V941)	• Monotherapy or with pembrolizumab (PD-1 inhibitor)	I	NSCLC, Pancreatic cancer, Colorectal Cancer with KRAS (G12D, G12V, G13D, or G12C) mutation	A study of mRNA-5671/V941 as monotherapy and in combination with pembrolizumab (V941–001)	NCT03948763

HLA: human leukocyte antigen; KRAS: Kirsten rat sarcoma viral oncogene homologue; NSCLC: non–small cell lung cancer; PD-1: programmed cell death 1; PD-L1: programmed cell death-ligand 1; PK: pharmacokinetics; TCR: T-cell receptor